XML 14 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Earnings/(Deficit)
FlexBiosys, Inc.
FlexBiosys, Inc.
Common Stock
FlexBiosys, Inc.
Additional Paid-in Capital
Metenova Holding AB
Metenova Holding AB
Common Stock
Metenova Holding AB
Additional Paid-in Capital
Balance at Dec. 31, 2021 $ 1,750,067 $ 553 $ 1,572,340 $ (16,886) $ 194,060            
Balance (in shares) at Dec. 31, 2021   55,321,457                  
Net Income (Loss) 185,959       185,959            
Issuance of common stock for debt conversion (6) $ 1 (7)                
Issuance of common stock for debt conversion (in shares)   21                  
Exercise of stock options and vesting of stock units 3,707 $ 3 3,704                
Exercise of stock options and vesting of stock units (in shares)   326,192                  
Tax withholding on vesting of restricted stock (17,018) $ (1) (17,017)                
Tax withholding on vesting of restricted stock (in shares)   (89,972)                  
Stock-based compensation expense 27,316   27,316                
Balance at Dec. 31, 2022 1,910,700 $ 556 1,547,266 (34,394) 397,272            
Balance (Accounting Standards Update 2020-06) at Dec. 31, 2022 (21,817)   (39,070)   17,253            
Balance (in shares) at Dec. 31, 2022   55,557,698                  
Translation adjustment (17,508)     (17,508)              
Net Income (Loss) 35,596       35,596            
Issuance of common stock for debt conversion (13)   (13)                
Issuance of common stock for debt conversion (in shares)   8                  
Exercise of stock options and vesting of stock units 1,076 $ 3 1,073                
Exercise of stock options and vesting of stock units (in shares)   251,886                  
Repurchase of common stock (14,386) $ (1) (14,385)                
Repurchase of common stock (in shares)   (92,090)                  
Issuance of commons stock pursuant to the acquisition           $ 5,465   $ 5,465 $ 8,104 $ 1 $ 8,103
Issuance of commons stock pursuant to the acquisition, (in shares)             31,415     52,299  
Tax withholding on vesting of restricted stock (13,227) $ (1) (13,226)                
Tax withholding on vesting of restricted stock (in shares)   (77,759)                  
Issuance of common stock pursuant to the Avitide, Inc. contingent consideration earnout payment 7,229   7,229                
Issuance of common stock pursuant to the Avitide, Inc.contingent consideration earnout payment (in shares)   42,621                  
Stock-based compensation expense 25,575   25,575                
Convertible note modification 2,791   2,791                
Deferred tax impact on conversion feature (651)   (651)                
Balance at Dec. 31, 2023 1,964,845 $ 558 1,569,227 (37,808) 432,868            
Balance (in shares) at Dec. 31, 2023   55,766,078                  
Translation adjustment (3,414)     (3,414)              
Net Income (Loss) (25,514)       (25,514)            
Issuance of common stock for debt conversion (114) $ 1 (115)                
Issuance of common stock for debt conversion (in shares)   100,944                  
Exercise of stock options and vesting of stock units 4,297 $ 3 4,294                
Exercise of stock options and vesting of stock units (in shares)   248,108                  
Tax withholding on vesting of restricted stock (9,883) $ (1) (9,882)                
Tax withholding on vesting of restricted stock (in shares)   (54,861)                  
Issuance of common stock pursuant to the Avitide, Inc. contingent consideration earnout payment 5,742   5,742                
Issuance of common stock pursuant to the Avitide, Inc.contingent consideration earnout payment (in shares)   31,408                  
Stock-based compensation expense 48,070   48,070                
Balance at Dec. 31, 2024 1,972,718 $ 561 $ 1,617,336 (52,533) $ 407,354            
Balance (in shares) at Dec. 31, 2024   56,091,677                  
Translation adjustment $ (14,725)     $ (14,725)